How to Get Dayvigo (Lemborexant) in Connecticut

Connecticut Allows Telehealth Prescriptions for Dayvigo

Connecticut law permits licensed prescribers to write Schedule IV controlled substance prescriptions via telehealth, which makes Dayvigo accessible without an in-person office visit. This applies to MDs, DOs, APRNs, and PAs who hold active Connecticut licenses and DEA registrations.

The Connecticut Department of Public Health updated its telehealth prescribing rules following the federal flexibilities introduced during the COVID-19 public health emergency. Under Connecticut General Statute §20-9a, a valid provider-patient relationship can be established through a real-time audio-video encounter. The prescriber must document the clinical evaluation, confirm the patient's identity and Connecticut address, and transmit the prescription electronically to a Connecticut-licensed pharmacy.

Telehealth platforms that operate in Connecticut typically require patients to complete a sleep intake questionnaire before the visit. This questionnaire covers sleep onset latency, wake-after-sleep-onset episodes, sleep duration, daytime impairment, and any history of parasomnias or substance use. The synchronous video visit itself usually lasts 15 to 25 minutes.

For patients who prefer in-person care, Connecticut has board-certified sleep medicine physicians across the state, concentrated in the Hartford, New Haven, and Stamford metro areas. A referral from a primary care provider is not required by most commercial insurers, though some HMO plans in the state do require one.

What Dayvigo Is and How It Works

Lemborexant is a dual orexin receptor antagonist (DORA). It blocks orexin-A and orexin-B from binding to OX1R and OX2R receptors, which suppresses the wakefulness signal rather than sedating the central nervous system broadly. This mechanism differs from older hypnotics like benzodiazepines and Z-drugs.

The FDA approved lemborexant in December 2019 for the treatment of insomnia characterized by difficulty with sleep onset, sleep maintenance, or both. The approval was based on two registrational trials. In the SUNRISE-1 trial (N=1,006), lemborexant 5 mg and 10 mg significantly reduced objective sleep onset latency compared with placebo at one month, with a least-squares mean difference of approximately 10 minutes for the 5 mg dose and 12 minutes for the 10 mg dose (P<0.001 for both comparisons vs. placebo). SUNRISE-1 also showed statistically significant improvements in wake-after-sleep-onset compared with the active comparator zolpidem extended-release 6.25 mg at the same time point.

The SUNRISE-2 trial (N=949) evaluated lemborexant over six months and demonstrated sustained efficacy without evidence of rebound insomnia or withdrawal symptoms upon discontinuation. Dr. Margaret Moline, then Eisai's Vice President of Clinical Research, noted at the time of approval: "The dual orexin receptor antagonist mechanism allows patients to fall asleep and stay asleep by turning down the wake drive rather than forcing sedation."

The recommended starting dose is 5 mg taken within 5 minutes of going to bed, with at least 7 hours of intended sleep remaining. The dose may be increased to 10 mg based on clinical response.

Insurance Coverage and Prior Authorization in Connecticut

Connecticut Medicaid covers Dayvigo with prior authorization (PA). Most commercial insurers in the state, including Anthem Blue Cross Blue Shield CT, Aetna, Cigna, and ConnectiCare, also cover Dayvigo but place it on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) formularies, and the majority require PA.

Prior authorization for Dayvigo in Connecticut typically requires the prescriber to document three things. First, the patient must have a confirmed diagnosis of insomnia disorder per DSM-5 or ICD-10 criteria. Second, the prescriber must show that the patient tried and failed, or has a documented contraindication to, at least one first-line agent. Connecticut Medicaid's preferred step therapy sequence starts with generic zolpidem or generic suvorexant before approving brand-name Dayvigo. Third, the prescriber must confirm that the patient does not have narcolepsy, severe hepatic impairment, or concurrent use of strong CYP3A inhibitors.

Processing time varies. Connecticut Medicaid must respond to a standard PA request within two business days and to an urgent request within 24 hours, per Connecticut's PA statute (§17b-262e). Commercial plans follow similar timelines. If a PA is denied, the prescriber can submit a peer-to-peer review or the patient can file a formal appeal through the insurer's grievance process.

Without insurance, Dayvigo's average retail price in Connecticut pharmacies ranges from $380 to $430 for a 30-day supply. Eisai offers a manufacturer savings card that reduces the out-of-pocket cost to as low as $30 per month for commercially insured patients, though this program excludes Medicare Part D and Medicaid beneficiaries.

Which Clinicians Can Prescribe Dayvigo in Connecticut

Connecticut grants independent prescriptive authority to several provider types, each of whom can prescribe a Schedule IV controlled substance like lemborexant.

Physicians (MDs and DOs) with active Connecticut medical licenses and DEA registrations may prescribe Dayvigo without restriction. Sleep medicine board certification is not required, meaning your primary care physician or internist can write the prescription.

Advanced Practice Registered Nurses (APRNs) in Connecticut have had full practice authority since 2014 under Public Act 14-12. APRNs do not need a collaborative agreement with a physician to prescribe Schedule IV controlled substances. This makes nurse practitioners a practical access point, especially in rural parts of Litchfield and Windham counties where sleep medicine specialists are scarce.

Physician Assistants (PAs) in Connecticut prescribe under a collaborative agreement with a supervising physician, but the supervising physician does not need to be physically present. PAs with DEA registrations can prescribe Dayvigo as part of their scope of practice.

One restriction applies across all provider types: the prescriber must conduct an adequate clinical evaluation before writing the prescription. For a telehealth encounter, Connecticut requires a synchronous audio-video visit. Audio-only telephone calls are not sufficient for an initial controlled substance prescription.

Labs and Clinical Evaluation Before Starting Dayvigo

No specific laboratory tests are mandated by the FDA label before prescribing lemborexant. The clinical evaluation focuses on confirming insomnia disorder diagnosis and ruling out conditions that mimic or worsen insomnia.

A thorough sleep history is the minimum. The prescriber should assess sleep onset latency, number and duration of nocturnal awakenings, total sleep time, sleep efficiency, and daytime consequences like fatigue, impaired concentration, or mood disturbance. Standardized tools such as the Insomnia Severity Index (ISI) or the Pittsburgh Sleep Quality Index (PSQI) help quantify baseline severity and track treatment response.

Some Connecticut prescribers order baseline labs for specific patient populations. For patients with suspected obstructive sleep apnea (OSA), the American Academy of Sleep Medicine (AASM) recommends a home sleep apnea test or in-lab polysomnography before starting any hypnotic, because treating the underlying apnea often resolves the insomnia. The AASM's 2017 clinical practice guideline for insomnia pharmacotherapy notes that DORAs like lemborexant are appropriate when cognitive behavioral therapy for insomnia (CBT-I) is insufficient or unavailable.

For patients with hepatic concerns, the Dayvigo label recommends checking liver function. Lemborexant is metabolized primarily by CYP3A4, and the recommended maximum dose is 5 mg in patients with moderate hepatic impairment (Child-Pugh B). The drug is not recommended in severe hepatic impairment.

A complete medication reconciliation is required. Lemborexant interacts with strong CYP3A inhibitors (e.g., itraconazole, clarithromycin), which are contraindicated, and moderate CYP3A inhibitors (e.g., fluconazole, diltiazem), which require dose adjustment to a 5 mg maximum.

503A Compounding Pharmacies in Connecticut

Connecticut licenses 503A compounding pharmacies under the Connecticut Department of Consumer Protection, Pharmacy Division. These pharmacies can compound lemborexant preparations when a patient has a specific clinical need that the commercially available 5 mg and 10 mg tablets do not meet, such as a requirement for a liquid formulation or a non-standard dose for patients with hepatic impairment.

A 503A pharmacy compounds medications based on an individual patient prescription. This is distinct from 503B outsourcing facilities, which can produce larger batches without patient-specific prescriptions. In Connecticut, 503A pharmacies must comply with USP <795> standards for non-sterile compounding.

Patients who use a 503A pharmacy for lemborexant should confirm three things with the pharmacy. The pharmacy must hold an active Connecticut compounding license. The pharmacist must source lemborexant active pharmaceutical ingredient (API) from an FDA-registered supplier. The compounded product must be dispensed with appropriate beyond-use dating per USP guidelines.

Insurance coverage for compounded lemborexant is inconsistent. Most commercial plans and Connecticut Medicaid do not cover compounded preparations when the FDA-approved commercial product is available in the prescribed dose. Patients typically pay out of pocket, with costs varying by pharmacy and formulation.

How Long It Takes to Receive Dayvigo in Connecticut

The timeline from initial consultation to medication in hand depends on three variables: the type of visit, insurance requirements, and pharmacy availability.

For a straightforward telehealth visit where the patient has no PA requirement (e.g., cash pay or a plan without step therapy), the prescription can be sent electronically to a pharmacy the same day. Most Connecticut retail pharmacies, including CVS, Walgreens, and independent pharmacies, stock Dayvigo or can order it within 24 to 48 hours. Total time: 1 to 3 days.

When prior authorization is required, add 2 to 5 business days. The prescriber submits the PA form, the insurer reviews it, and upon approval the pharmacy can dispense the medication. If the PA is denied and a peer-to-peer review is needed, the process can extend to 7 to 14 days.

Mail-order pharmacy is another option. Some Connecticut patients use mail-order through their insurance plan's preferred pharmacy benefit manager (PBM). Mail-order can offer a 90-day supply at a lower per-unit cost, but initial delivery takes 7 to 10 business days after prescription approval.

For the fastest access, patients paying out of pocket through a telehealth provider can receive a same-day electronic prescription and pick up Dayvigo at a local pharmacy that has it in stock. Calling the pharmacy ahead to confirm availability saves an extra trip.

Transferring a Dayvigo Prescription to Connecticut

Patients relocating to Connecticut or visiting for an extended period can transfer an existing Dayvigo prescription from another state. Connecticut follows DEA regulations for interstate transfer of Schedule IV prescriptions.

The receiving Connecticut pharmacy contacts the originating out-of-state pharmacy to verify the prescription details, remaining refills, and prescriber information. The transfer must be documented by both pharmacies. Electronic prescription transfers between pharmacy chains (e.g., CVS to CVS) are typically completed within one business day.

One limitation applies: if the original prescription was written by a prescriber not licensed in Connecticut, and the patient needs a new prescription (not a transfer of remaining refills), the patient must establish care with a Connecticut-licensed provider. A telehealth visit with a Connecticut-licensed prescriber is the most efficient path in this scenario.

Patients moving permanently to Connecticut should plan ahead. Schedule a telehealth or in-person visit with a new Connecticut provider before the last refill runs out. A gap in medication can cause rebound insomnia, though the SUNRISE-2 trial data showed that abrupt discontinuation of lemborexant did not produce significant rebound effects at the group level. Individual responses vary.

Safety Considerations Specific to Connecticut Patients

Connecticut participates in the Prescription Monitoring Program (PMP), which tracks all Schedule II through V controlled substance dispensing in the state. Prescribers are required to check the Connecticut PMP before writing a new controlled substance prescription. This step is built into the workflow and does not add meaningful delay.

The most common adverse effects of lemborexant reported in clinical trials were somnolence (reported in 10% of patients on the 10 mg dose vs. 1% on placebo in SUNRISE-1), headache, and fatigue. Complex sleep behaviors, including sleepwalking and sleep-driving, carry a boxed warning on the FDA label, though these events were rare in clinical trials.

The Endocrine Society's 2017 clinical practice guideline on the evaluation and management of sleep disorders highlights that patients with comorbid depression should be monitored closely when starting any hypnotic, as worsening of depression and suicidal ideation have been reported with sleep medications as a class. Connecticut's 2-1-1 system and the 988 Suicide and Crisis Lifeline are available 24/7 for patients experiencing psychiatric symptoms.

Patients should not take lemborexant with alcohol or other CNS depressants. Connecticut providers typically counsel patients on this point during the prescribing visit and include it in the pharmacy's dispensing instructions.

The recommended follow-up interval is 4 to 6 weeks after initiation. The prescriber reassesses sleep outcomes using the ISI or PSQI, screens for adverse effects, and determines whether the dose should remain at 5 mg or increase to 10 mg.